Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures-Reference-Cited by-同舟云学术

Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures

Published:2010-05-13 Issue:1 Volume:29 Page:37-43
ISSN:0914-8779
Container-title:Journal of Bone and Mineral Metabolism
language:en
Short-container-title:J Bone Miner Metab

Author:

Shiraki Masataka,Kuroda Tatsuhiko,Miyakawa Nobuaki,Fujinawa Naohito,Tanzawa Kazumasa,Ishizuka Akiko,Tanaka Shiro,Tanaka Yukari,Hosoi Takayuki,Itoi Eiji,Morimoto Shigeto,Itabashi Akira,Sugimoto Toshitsugu,Yamashita Toshihiko,Gorai Itsuo,Mori Satoshi,Kishimoto Hideaki,Mizunuma Hideki,Endo Naoto,Nishizawa Yoshiki,Takaoka Kunio,Ohashi Yasuo,Ohta Hiroaki,Fukunaga Masao,Nakamura Toshitaka,Orimo Hajime

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,General Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s00774-010-0188-x.pdf

Reference28 articles.

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795

2. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384–1392

3. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541

4. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082

5. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Denosumab with Romosozumab in the Treatment of Male Osteoporosis: A Retrospective Cohort Study;2024-06-20

2. Secondary fracture and mortality risk with very high fracture risk osteoporosis and proximal femoral fracture;Journal of Bone and Mineral Metabolism;2024-02-03

3. Radiofrequency Echographic Multispectrometry (REMS) can Overcome the Effects of Structural Internal Artifacts and Evaluate Bone Fragility Accurately;Calcified Tissue International;2023-12-21

4. Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients;Calcified Tissue International;2023-04-10

5. Accuracy of the Fracture Risk Assessment Tool for judging pharmacotherapy initiation for primary osteoporosis;Journal of Bone and Mineral Metabolism;2022-08-10